Literature DB >> 26041662

Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.

C Requejo1, J A Ruiz-Ortega, H Bengoetxea, A Garcia-Blanco, E Herrán, A Aristieta, M Igartua, L Ugedo, J L Pedraz, R M Hernández, J V Lafuente.   

Abstract

Administration of various neurotrophic factors is a promising strategy against Parkinson's disease (PD). An intrastriatal infusion of 6-hydroxidopamine (6-OHDA) in rats is a suitable model to study PD. This work aims to describe stereological parameters regarding rostro-caudal gradient, in order to characterize the model and verify its suitability for elucidating the benefits of therapeutic strategies. Administration of 6-OHDA induced a reduction in tyrosine hidroxylase (TH) reactivity in the dorsolateral part of the striatum, being higher in the caudal section than in the rostral one. Loss of TH-positive neurons and axodendritic network was highly significant in the external third of substantia nigra (e-SN) in the 6-OHDA group versus the saline one. After the administration of nanospheres loaded with neurotrophic factors (NTF: vascular endothelial growth factor (VEGF) + glial cell line-derived neurotrophic factor (GDNF)), parkinsonized rats showed more TH-positive fibers than those of control groups; this recovery taking place chiefly in the rostral sections. Neuronal density and axodendritic network in e-SN was more significant than in the entire SN; the topographical analysis showed that the highest difference between NTF versus control group was attained in the middle section. A high number of bromodeoxyuridine (BrdU)-positive cells were found in sub- and periventricular areas in the group receiving NTF, where most of them co-expressed doublecortin. Measurements on the e-SN achieved more specific and significant results than in the entire SN. This difference in rostro-caudal gradients underpins the usefulness of a topological approach to the assessment of the lesion and therapeutic strategies. Findings confirmed the neurorestorative, neurogenic, and synergistic effects of VEGF+GDNF administration.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26041662     DOI: 10.1007/s12035-015-9234-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  46 in total

1.  Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian.

Authors:  C Barcia; V Bautista; A Sánchez-Bahillo; E Fernández-Villalba; B Faucheux; M Poza y Poza; A Fernandez Barreiro; E C Hirsch; M-T Herrero
Journal:  J Neural Transm (Vienna)       Date:  2005-01-24       Impact factor: 3.575

2.  Distribution of dopamine transporter immunoreactive fibers in the human amygdaloid complex.

Authors:  María García-Amado; Lucía Prensa
Journal:  Eur J Neurosci       Date:  2013-09-16       Impact factor: 3.386

3.  Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.

Authors:  C Rosenblad; D Kirik; A Björklund
Journal:  Exp Neurol       Date:  2000-02       Impact factor: 5.330

Review 4.  Diagnosis and treatment of Parkinson disease: molecules to medicine.

Authors:  Joseph M Savitt; Valina L Dawson; Ted M Dawson
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

5.  Early-stage Parkinson's disease: to treat or not to treat.

Authors:  J Jankovic; I Shoulson; W J Weiner
Journal:  Neurology       Date:  1994-03       Impact factor: 9.910

6.  Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin.

Authors:  M L Block; G Li; L Qin; X Wu; Z Pei; T Wang; B Wilson; J Yang; J S Hong
Journal:  FASEB J       Date:  2006-02       Impact factor: 5.191

Review 7.  The origins of oxidant stress in Parkinson's disease and therapeutic strategies.

Authors:  Dalton James Surmeier; Jaime N Guzman; Javier Sanchez-Padilla; Joshua A Goldberg
Journal:  Antioxid Redox Signal       Date:  2010-12-15       Impact factor: 8.401

8.  Effects of intraventricular infusion of vascular endothelial growth factor on cerebral blood flow, edema, and infarct volume.

Authors:  M R Harrigan; S R Ennis; S E Sullivan; R F Keep
Journal:  Acta Neurochir (Wien)       Date:  2003-01       Impact factor: 2.216

9.  Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease.

Authors:  E Garbayo; C N Montero-Menei; E Ansorena; J L Lanciego; M S Aymerich; M J Blanco-Prieto
Journal:  J Control Release       Date:  2008-12-25       Impact factor: 9.776

10.  Sham transplantation protects against 6-hydroxydopamine-induced dopaminergic toxicity in rats: behavioral and morphological evidence.

Authors:  S Przedborski; M Levivier; V Kostic; V Jackson-Lewis; A Dollison; D M Gash; S Fahn; J L Cadet
Journal:  Brain Res       Date:  1991-06-07       Impact factor: 3.252

View more
  7 in total

1.  Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease.

Authors:  C Requejo; J A Ruiz-Ortega; H Cepeda; A Sharma; H S Sharma; A Ozkizilcik; R Tian; H Moessler; L Ugedo; J V Lafuente
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

2.  Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A García-Blanco; E Herrán; A Aristieta; M Igartua; J L Pedraz; L Ugedo; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

Review 3.  Vascular endothelial growth factor: a neurovascular target in neurological diseases.

Authors:  Christian Lange; Erik Storkebaum; Carmen Ruiz de Almodóvar; Mieke Dewerchin; Peter Carmeliet
Journal:  Nat Rev Neurol       Date:  2016-07-01       Impact factor: 42.937

4.  Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson's Disease.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; S Bulnes; L Ugedo; J V Lafuente
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

5.  Adaptive Changes in the Sensitivity of the Dorsal Raphe and Hypothalamic Paraventricular Nuclei to Acute Exercise, and Hippocampal Neurogenesis May Contribute to the Antidepressant Effect of Regular Treadmill Running in Rats.

Authors:  Ayu Nishii; Seiichiro Amemiya; Natsuko Kubota; Takeshi Nishijima; Ichiro Kita
Journal:  Front Behav Neurosci       Date:  2017-11-24       Impact factor: 3.558

Review 6.  Neurotrophic Factors in Parkinson's Disease: Clinical Trials, Open Challenges and Nanoparticle-Mediated Delivery to the Brain.

Authors:  Olesja Bondarenko; Mart Saarma
Journal:  Front Cell Neurosci       Date:  2021-06-02       Impact factor: 5.505

Review 7.  Growth Factor Therapy for Parkinson's Disease: Alternative Delivery Systems.

Authors:  Sarah Jarrin; Abrar Hakami; Ben Newland; Eilís Dowd
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.